We believe Creo Medical is at a significant commercial inflection point based upon increased adoption of its core device portfolio and validation of its Kamaptive technology through two announced licensing agreements. We expect these achievements to become increasingly evident in the company's financial reports providing quantitative support to our investment thesis. With this report we have extended our financial forecasts to FY27E, providing a view on the revenue development to c£100m and the ....
23 Nov 2022
Cenkos: Creo Medical Group Plc - Delivering the strategy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Creo Medical Group Plc - Delivering the strategy
Creo Medical Group Plc (CREO:LON) | 34.8 0 0.0% | Mkt Cap: 125.6m
- Published:
23 Nov 2022 -
Author:
Chris Donnellan -
Pages:
39
We believe Creo Medical is at a significant commercial inflection point based upon increased adoption of its core device portfolio and validation of its Kamaptive technology through two announced licensing agreements. We expect these achievements to become increasingly evident in the company's financial reports providing quantitative support to our investment thesis. With this report we have extended our financial forecasts to FY27E, providing a view on the revenue development to c£100m and the ....